Harmony Biosciences Holdings Incorporated files for IPO.

IPO of Harmony Biosciences Holdings Incorporated will take place on August 18 2020. Harmony Biosciences is a pharmaceutical company focused on developing innovative therapies for patients with rare neurological disorder. The company’s main product is WAKIX (pitolisant). It is a first in its class molecule with a novel mechanism of action, specifically designed to increase histamine signaling in the brain. WAKIX is the first and only approved product for patients with narcolepsy that is not scheduled in the list of controlled substances. 
The estimated value of the company after IPO will be USD1.9 billion.
IPO bookrunners listed include Goldman Sachs, Jefferies and Piper Sandler.